logo

Enter Symbol

PHASE FWD(NSDQ:PFWD)
Phase Forward is a provider of integrated enterprise-level software products, services, and hosted solutions for use in the clinical trial component of its customers'' global research and development initiatives. Phase Forward''s customers include pharmaceutical, biotechnology, and medical device companies, as well as academic institutions, clinical research organizations, and other entities engaged in clinical trials.
# Employees: 718
Address: 880 Winter Street,Waltham,MA,USA
Phone: 781-890-7878
Fax: 781 890-4848
Website: www.phaseforward.com
Email: investorinfo@phaseforward.com
Sector: Computer and Technology
Industry: COMP-SOFTWARE
Executive Officers
Paul A. Bleicher M.D. ()
PH.D.Chmn. (Robert K. Weiler)
Presi.; C.E.O.; Dir. (Rodger Weismann)
Sr. V.P.; C.F.O.; Princ. Acctg. Off. (Axel Bichara)
Dir. (James I. Cash Jr.,,h.D.Dir.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 2/4/2010
Mean EPS (Next Qtr): $0.08
Mean EPS (Year): $0.33
Mean Estimate(Long Term): $21.36
P/E Ratio(Based on EPS estimate): 47.590
Number of Estimates: 9
Shares Performance
Period PFWD Compare to S&P
YTD 26.28 % 4.51 %
4 Weeks 17.46 % 16.19 %
12 Weeks 22.84 % 15.81 %
Shares Information
Analyst Coverage: Y
Avg Volume: 397105
Shares Outstanding: 43M
Market Cap: $0.68B
52 Week High: $17.04
52 Week Low: $9.74
P/E Ratio: 49.410
PEG Ratio: 2.230
Split: On 1/1/1990 PFWD split by factor of 0.250
Earnings Performance
EPS Growth in Last Quarter: -25.00 %
EPS Growth in Last Year: -25.00 %
Sales Growth in Last Quarter: 2.05 %
Sales Growth in Last Quarter: 23.56 %
Financials
Qtr Book Value: $2.67
Cash Flow/Share: $26.90
Change in Payout Ratio: 0.000
Price/Sales: 3.380
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia